CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Income Statement [Abstract]
Net revenues	$ 134,695	$ 101,828	$ 494,366
Cost of revenues	26,385	24,496	106,501
Gross profit	108,310	77,332	387,865
Operating costs and expenses:
Research, development and clinical trials	45,916	25,271	132,010
Sales and marketing	31,357	28,834	118,017
General and administrative	31,125	26,608	107,437
Total operating costs and expenses	108,398	80,713	357,464
Operating income (loss)	(88)	(3,381)	30,401
Financial expenses (income), net	2,646	2,432	12,299
Income (loss) before income tax	(2,734)	(5,813)	18,102
Income tax	1,394	(9,765)	(1,706)
Net income (loss)	$ (4,128)	$ 3,952	$ 19,808
Basic net income (loss) per ordinary share (in usd per share)	$ (0.04)	$ 0.04	$ 0.20
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	102,633,545	99,877,567	100,930,866
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.04)	$ 0.04	$ 0.18
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	102,633,545	108,100,623	108,877,648